An extracellular polysaccharide of Bifidobacterium adolescentis, its extraction method and application

By extracting and purifying extracellular polysaccharides from Bifidobacterium adolescentis, the problem of unclear structure and activity in existing technologies has been solved, and polysaccharides with immunomodulatory effects have been obtained for the preparation of immunomodulatory products.

CN118459620BActive Publication Date: 2026-11-17SUN YAT SEN UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410611326.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-16
Publication Date
2026-11-17
Estimated Expiration
2044-05-16

AI Technical Summary

Technical Problem

Current research on microbial extracellular polysaccharides lacks products with well-defined structures and biological activity, which limits their application in the food and pharmaceutical fields and makes their development difficult.

Method used

An extracellular polysaccharide was extracted from Bifidobacterium adolescentis and purified through fermentation culture, alcohol precipitation, enzymatic hydrolysis, dialysis, anion exchange column chromatography, and gel column chromatography to obtain a polysaccharide with immunomodulatory activity.

Benefits of technology

The extracted extracellular polysaccharide from Bifidobacterium adolescentis can promote the proliferation and nitric oxide secretion of RAW 264.7 cells, enhance phagocytic activity, and has significant immunomodulatory activity, making it suitable for the preparation of immunomodulatory products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118459620B_ABST
    Figure CN118459620B_ABST
Patent Text Reader

Abstract

This invention discloses an extracellular polysaccharide of *Bifidobacterium adolescentis*, its extraction method, and its applications. The invention involves treating the fermentation broth of *Bifidobacterium adolescentis* with alcohol precipitation, protein removal, anion exchange column chromatography, and gel column chromatography to extract an immunomodulatory polysaccharide, namely the *Bifidobacterium adolescentis* extracellular polysaccharide described in this invention. This polysaccharide can promote the proliferation of RAW 264.7 cells and their nitric oxide secretion, while also enhancing the phagocytic activity of RAW 264.7 cells, exhibiting immunomodulatory activity. It can be used to prepare immunomodulatory products, which is beneficial for the development of immunomodulatory products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of microbial extracellular polysaccharide technology. More specifically, it relates to an extracellular polysaccharide of Bifidobacterium adolescentis, its extraction method, and its applications. Background Technology

[0002] While probiotics such as Bifidobacterium can promote the health of the host, as a type of living microorganism, their metabolism in the body is difficult to control and may cause safety issues such as bacterial infections, which limits their further application in the food and pharmaceutical fields.

[0003] Microbial extracellular polysaccharides (EPS) are a class of polymers secreted by microorganisms during metabolism, possessing various biological activities such as antibacterial, antiviral, antioxidant, antitumor, anti-aging, and cholesterol-lowering effects. Compared with live microorganisms, microbial EPS has advantages such as easier control of production conditions and safety without toxicity. Therefore, the development and utilization of microbial EPS is receiving increasing attention. However, current research on microbial EPS mainly focuses on the screening of high-yielding strains and the optimization of production conditions, with fewer reports on the structure and physiological activities of the polysaccharides. In other words, there is a lack of microbial EPS with clearly defined structures and activities, which hinders the industrial production and application of these polysaccharides.

[0004] Although many types of microorganisms can produce extracellular polysaccharides, only a dozen or so have real application value and have been or are close to industrial production. Moreover, the biological activity of polysaccharides is affected by factors such as their monosaccharide composition, molecular weight, glycosidic bond type, branching degree and spatial conformation. The relationship between polysaccharide structural characteristics and their activity has not been fully clarified. This makes the development of microbial extracellular polysaccharides highly uncertain and increases the difficulty of developing microbial extracellular polysaccharides with well-defined structures and biological activity. Summary of the Invention

[0005] This invention provides an extracellular polysaccharide of Bifidobacterium adolescentis, its extraction method, and its application, enriching the knowledge of microbial extracellular polysaccharides with well-defined structures and activities.

[0006] The first objective of this invention is to provide a method for extracting extracellular polysaccharides from Bifidobacterium adolescentis.

[0007] The second objective of this invention is to provide an extracellular polysaccharide of Bifidobacterium adolescentis.

[0008] A third objective of this invention is to provide the application of the aforementioned Bifidobacterium adolescentis extracellular polysaccharide in the preparation of immunomodulatory products.

[0009] The fourth objective of this invention is to provide an immunomodulatory product.

[0010] The above-mentioned objective of this invention is achieved through the following technical solution:

[0011] This invention extracts an extracellular polysaccharide with immunomodulatory activity from *Bifidobacterium adolescentis*. Analysis of the monosaccharide composition and structure of this polysaccharide, and comparison with existing bacterial extracellular polysaccharides, reveals that this extracellular polysaccharide is a novel one. This extracellular polysaccharide can promote the proliferation of RAW 264.7 cells and their nitric oxide (NO) secretion, while also enhancing the phagocytic activity of RAW 264.7 cells, exhibiting immunomodulatory activity. It can be used to prepare immunomodulatory products. Therefore, this invention seeks protection for the *Bifidobacterium adolescentis* extracellular polysaccharide, its extraction method, and its applications.

[0012] This invention provides a method for extracting extracellular polysaccharides from Bifidobacterium adolescentis, comprising the following steps:

[0013] S1. Ferment and culture Bifidobacterium adolescentis and collect the fermentation broth;

[0014] S2. Remove the bacterial cells from the fermentation broth and inactivate the enzymes contained therein, precipitate with ethanol, and collect the precipitate;

[0015] S3. Dissolve the precipitate obtained in step S2, add papain for enzymatic hydrolysis, remove protein with Sevag reagent, and then perform dialysis and depigmentation treatment in sequence to obtain decolorized crude polysaccharide.

[0016] S4. The decolorized crude polysaccharide was separated and purified by anion exchange column chromatography, eluted with ultrapure water, and the fraction obtained by elution with ultrapure water was collected.

[0017] S5. The fraction obtained in step S4 was separated and purified by gel column chromatography. Ultrapure water was used for elution. The absorbance of the eluent at 490 nm was detected by the phenol-sulfuric acid method and the elution curve was plotted. The eluent fractions from the first peak to the peak tip of the first four tubes were collected.

[0018] Specifically, the culture medium used for the fermentation culture of Bifidobacterium adolescentis in step S1 is MRS broth medium, which contains 0.5 g / L L-cysteine ​​hydrochloride.

[0019] Specifically, the fermentation culture described in step S1 involves culturing the activated Bifidobacterium adolescentis for two generations at an inoculum of 2%, followed by fermentation culture at 37°C under anaerobic conditions for 60 hours.

[0020] Specifically, step S2 involves removing the bacterial cells from the fermentation broth by centrifugation; the method for inactivating the enzymes is boiling for 25–35 minutes.

[0021] More specifically, the method to inactivate the contained enzymes is to boil at 100°C for 25–35 minutes.

[0022] Specifically, in step S2, 3.8 to 4.2 times the volume of ethanol is added for alcohol precipitation.

[0023] More specifically, the ethanol is 95% ethanol, left to stand overnight at 4°C.

[0024] Specifically, in step S3, the precipitate obtained in step S2 is dissolved in water; the final concentration of papain is 1.8–2.2 mg / mL, and the enzyme is hydrolyzed at 58–60 °C for 55–65 min.

[0025] Specifically, in step S3, the enzyme is further inactivated by boiling after enzymatic hydrolysis.

[0026] More specifically, the enzyme inactivation is performed at 100°C for 15 minutes.

[0027] Specifically, the Sevag reagent in step S3 consists of chloroform and n-butanol in a volume ratio of 4:1.

[0028] Specifically, in step S3, after inactivating the enzyme at 100℃ for 15 min, the supernatant is collected by centrifugation. Sevag reagent is added to the supernatant to remove protein. The amount of Sevag reagent used is 1 / 5 to 1 / 3 of the supernatant volume.

[0029] Specifically, after removing all proteins, the resulting supernatant is evaporated to remove organic solvents, followed by the addition of water solvent, and then dialyzed in a dialysis bag with a molecular weight cutoff of 3500 Da.

[0030] Specifically, the dialysis time is 36 hours, with the water changed every 2 to 4 hours.

[0031] Specifically, the dialysis solution was freeze-dried to obtain crude extracellular polysaccharide of Bifidobacterium adolescentis, and the obtained crude extracellular polysaccharide was then used to remove pigments using AB-8 macroporous adsorption resin.

[0032] Specifically, the anion exchange column chromatography used in step S4 is DEAE cellulose DE-52 anion exchange column chromatography.

[0033] Specifically, the gel column chromatography used in step S5 is Sephacryl S-500HR propylene dextran gel column chromatography.

[0034] Specifically, in step S5, the flow rate of ultrapure water elution is 0.5 mL / min, and 4 mL is collected from each tube.

[0035] Specifically, the elution fraction collected in step S5 is lyophilized by dialysis to obtain the extracellular polysaccharide of Bifidobacterium adolescentis described in this invention.

[0036] Specifically, the molecular weight cutoff for dialysis is 3500 Da, the dialysis time is 36 hours, and the water is changed every 2 to 4 hours.

[0037] Preferably, among the elution fractions collected from the first peak to the peak tip in the last four tubes, the elution fractions with the highest absorbance (top 85%) are selected, as these elution fractions have relatively higher purity.

[0038] The present invention also provides an extracellular polysaccharide of Bifidobacterium adolescentis, which is obtained by the extraction method described above in the present invention.

[0039] In a specific embodiment of the present invention, the reproducible primary structural unit of the extracellular polysaccharide of Bifidobacterium adolescentis includes: Glcp-(1→,→3-Glcp-(1→,→3)-Manp-(1→,→2)-Galp-(1→,→2)-Glcp-(1→,→4)-Galp-(1→,→4)-Glcp-(1→ and→2,6)-Galp-(1→, a total of 8 sugar residues.

[0040] Specifically, the primary structure of the extracellular polysaccharide of *Bifidobacterium adolescentis* is as follows:

[0041]

[0042] Its main chain consists of β-1,3-Glcp, β-1,2-Glcp, α-1,3-Manp, α-1,4-Galp, α-1,4-Glcp and α-1,6-Galp, among which the O-2 position of α-1,6-Galp contains a branch chain, which consists of α-1,2-Galp and α-1-Glcp.

[0043] In one specific embodiment of the present invention, the total sugar content of the extracellular polysaccharide of Bifidobacterium adolescentis is 97.56% ± 1.40%.

[0044] In one specific embodiment of the present invention, the molecular weight of the extracellular polysaccharide of *Bifidobacterium adolescentis* is 9.69 × 10⁻⁶. 6 Da.

[0045] In a specific embodiment of the present invention, the extracellular polysaccharide of Bifidobacterium adolescentis is mainly composed of mannose, glucose and galactose, and the molar ratio of each component is 0.11:4.3:1.3.

[0046] The extracellular polysaccharide of Bifidobacterium adolescentis described in this invention can promote the proliferation of RAW 264.7 cells and their NO secretion, while also enhancing the phagocytic activity of RAW 264.7 cells, thus exhibiting immune-enhancing activity.

[0047] Therefore, this invention seeks protection for the use of the aforementioned Bifidobacterium adolescentis extracellular polysaccharide in the preparation of immunomodulatory products.

[0048] The present invention also provides an immunomodulatory product containing the extracellular polysaccharide of Bifidobacterium adolescentis described in the present invention.

[0049] Specifically, the immune regulation refers to enhancing the body's immunity.

[0050] More specifically, the immune regulation is to promote the proliferation of RAW 264.7 cells and enhance their phagocytic activity.

[0051] The present invention has the following beneficial effects:

[0052] This invention extracts an immunomodulatory polysaccharide from the fermentation broth of *Bifidobacterium adolescentis* through alcohol precipitation, protein removal, anion exchange column chromatography, and gel column chromatography. This polysaccharide promotes the proliferation of RAW 264.7 cells and their NO secretion, while also enhancing the phagocytic activity of RAW 264.7 cells, thus exhibiting immunomodulatory activity. It can be used to prepare immunomodulatory products, which is beneficial for the development of immunomodulatory products. Attached Figure Description

[0053] Figure 1 Elution curve of crude extracellular polysaccharide of Bifidobacterium adolescentis by DEAE cellulose DE-52 anion exchange column chromatography.

[0054] Figure 2 Elution curve of BEP-1 by Sephacryl S-500HR propylene dextran gel column chromatography.

[0055] Figure 3 This is the HPGPC peak diagram for BEP-1A.

[0056] Figure 4 The figures show chromatograms of the mixed monosaccharide standard and the monosaccharide composition of BEP-1A; A in the figure is the chromatogram of the mixed monosaccharide standard; B in the figure is the chromatogram of the monosaccharide composition of BEP-1A.

[0057] Figure 5 This is the infrared spectrum of BEP-1A.

[0058] Figure 6 For BEP-1A 1 H spectrum.

[0059] Figure 7 For BEP-1A 13 C-spectrum.

[0060] Figure 8The HSQC spectrum of BEP-1A is shown.

[0061] Figure 9 For BEP-1A 1 H- 1 H COSY spectrum.

[0062] Figure 10 The HMBC spectrum of BEP-1A.

[0063] Figure 11 The results show the effect of BEP-1A on the proliferation of RAW 264.7 cells; compared with the blank control group, * P < 0.05; ** P < 0.01.

[0064] Figure 12 The results show the effect of BEP-1A on nitric oxide release in RAW 264.7 cells; compared with the blank control group, * P < 0.05; ** P < 0.01.

[0065] Figure 13 The results show the effect of BEP-1A on the phagocytic function of RAW 264.7 cells, as detected by the FITC-Dextran phagocytosis assay. Detailed Implementation

[0066] The present invention will be further described below with reference to the accompanying drawings and specific embodiments, but the embodiments do not limit the present invention in any way. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in this technical field.

[0067] Unless otherwise specified, all reagents and materials used in the following examples are commercially available.

[0068] Example 1: Extraction of extracellular polysaccharides from Bifidobacterium adolescentis

[0069] 1. Extraction of extracellular polysaccharides from Bifidobacterium adolescentis

[0070] The *Bifidobacterium adolescentis* used in this embodiment is strain ATCC 15703 (purchased from Guangdong Provincial Microbial Culture Collection Center). The extraction process of the extracellular polysaccharide of *Bifidobacterium adolescentis* is as follows:

[0071] S1. The frozen Bifidobacterium adolescentis strain stored at -80℃ was inoculated into MRS broth medium (the MRS broth medium was purchased from Qingdao Haibo Biotechnology Co., Ltd., and the MRS broth medium used for culture contained 0.5 g / L L-cysteine ​​hydrochloride) for activation. After activation for 24 h, it was cultured in MRS broth medium at an inoculation amount of 2% for two generations, and fermented at 37℃ under anaerobic conditions for 60 h.

[0072] S2. After fermentation culture is completed, centrifuge the fermentation culture to remove the cells, and boil the supernatant at 100℃ for 30 min; centrifuge again to collect the supernatant, concentrate under reduced pressure, add 4 times the volume of 95% ethanol to the concentrate while stirring, let stand at 4℃ overnight to precipitate polysaccharides, and centrifuge to collect the polysaccharide precipitate.

[0073] S3. Dissolve the polysaccharide precipitate in water, add papain to a final concentration of 2 mg / mL, stir at 60℃ for 1 h, then inactivate the enzyme at 100℃ for 15 min; centrifuge and collect the supernatant, add 1 / 4 volume of Sevag reagent (composed of chloroform and n-butanol in a volume ratio of 4:1), vortex to mix, centrifuge and collect the supernatant again, repeat the operation until the intermediate protein emulsion layer disappears; evaporate the obtained supernatant to dryness to remove the organic solvent; dissolve in water and place in a dialysis bag with a molecular weight cutoff of 3500 Da for dialysis for 36 h, changing the water every 2-4 h; freeze-dry the dialysis solution to obtain the crude extracellular polysaccharide of Bifidobacterium adolescentis, and then remove the pigment from the obtained crude extracellular polysaccharide using AB-8 macroporous adsorption resin;

[0074] S4. The decolorized extracellular crude polysaccharide was fractionated and purified by DEAE cellulose DE-52 anion exchange column chromatography. The extracellular crude polysaccharide was dissolved in an appropriate amount of ultrapure water to prepare an extracellular crude polysaccharide solution with a final concentration of 50 mg / mL. The supernatant was collected by centrifugation, filtered through a 0.45 μm microporous membrane, and loaded into a DEAE cellulose DE-52 anion exchange column (25 × 30 cm, packing material purchased from Beijing Solarbio Science & Technology Co., Ltd.) at a loading volume of 10 mL. The column was eluted sequentially with ultrapure water, 0.1 M, 0.3 M, and 0.5 M NaCl solutions at a flow rate of 1 mL / min, and 8 mL was collected from each tube. The absorbance of the eluent at 490 nm was detected by the phenol-sulfuric acid method, and an elution curve was plotted. The fractions of each gradient were combined according to the elution curve, dialyzed, and lyophilized for storage.

[0075] The elution curve of extracellular crude polysaccharide of Bifidobacterium adolescentis by DEAE cellulose DE-52 anion exchange column chromatography is shown in the figure below. Figure 1 As shown. By Figure 1 As can be seen, the present invention combines the components of each gradient according to the elution curve to obtain a total of 3 components, which are named BEP-1, BEP-2 and BEP-3 respectively. Finally, the component BEP-1 obtained by elution with ultrapure water is further purified by Sephacryl S-500HR propylene dextran gel column chromatography.

[0076] S5. Further purification of the fraction obtained in step S4 was performed using Sephacryl S-500HR propylene dextran gel column chromatography. The fraction (BEP-1) obtained by elution with ultrapure water in step S4 was dissolved in an appropriate amount of ultrapure water to prepare a solution with a final concentration of 10 mg / mL. The solution was then loaded onto a Sephacryl S-500HR propylene dextran gel column (1.5 × 100 cm, packing material purchased from Shanghai Yuanye Biotechnology Co., Ltd.). Ultrapure water was used for elution at a flow rate of 0.5 mL / min, and 4 mL was collected from each tube for a total of 50 tubes. The absorbance of the eluent at 490 nm was detected by the phenol-sulfuric acid method and an elution curve was plotted. Based on the plotted elution curve, the same fractions were combined and purified by dialysis (method as before) and lyophilization to obtain the purified fraction with a single molecular weight.

[0077] The elution curve of BEP-1 by Sephacryl S-500HR propylene dextran gel column chromatography is shown below. Figure 2 As shown. By Figure 2 It can be seen that the present invention separated two components. The eluted components from the first peak to the peak tip of the first four tubes were collected for subsequent experiments. In this embodiment, the present invention ultimately selected the components collected from tubes 14 to 19 for subsequent experiments, and named the obtained components as Bifidobacterium adolescentis extracellular polysaccharide BEP-1A.

[0078] 2. Analysis of the extracellular polysaccharide BEP-1A of Bifidobacterium adolescentis

[0079] (1) Determination of total sugar content in BEP-1A

[0080] Using glucose dried to constant weight as a reference standard, the total sugar content of BEP-1A was determined by the phenol-sulfuric acid method. In this invention, a standard curve was plotted with the mass of the glucose reference standard as the x-axis and the absorbance value as the y-axis, and a regression equation was fitted. The obtained regression equation is: y = 7.316x + 0.0708, (R0...)0 2 =0.9961). Substituting the absorbance of BEP-1A into the regression equation, its total sugar content was calculated to be 97.56% ± 1.40%.

[0081] (2) Determination of the molecular weight of BEP-1A

[0082] The molecular weight of BEP-1A was determined by high-performance gel permeation chromatography (HPGPC). Dextran standards and samples of different molecular weights were prepared into 1 mg / mL solutions with water, filtered through a 0.22 μm microporous membrane, and then analyzed by high-performance liquid chromatography. The chromatographic conditions used were as follows: Instrument: Waters e2695 high-performance liquid chromatograph; Column: PolySep-GFC-P4000 (300 mm × 7.8 mm, Phenomenex); Mobile phase: ultrapure water; Flow rate: 1.0 mL / min; Injection volume: 20 μL; Detector: evaporative light scattering detector.

[0083] The HPGPC peak diagram of BEP-1A is as follows: Figure 3 As shown. A linear equation was established with the retention time of dextran standards of different molecular weights as the x-axis and the logarithm of the molecular weight (lgMw) as the y-axis. The resulting linear equation is: y = -0.8044x + 10.676, (R... 2 =0.9939). Substituting the retention time of BEP-1A into the linear equation yields its molecular weight, which is 9.69 × 10⁻⁶. 6 Da.

[0084] (3) Compositional analysis of BEP-1A monosaccharides

[0085] The monosaccharide composition of BEP-1A was determined by high-performance liquid chromatography (HPLC) combined with pre-column derivatization using 1-phenyl-3-methyl-5-pyrazolone (PMP). Specifically, a certain amount of monosaccharide standard solution was taken, and 0.5 M PMP methanol solution and 0.3 M NaOH solution were added. After mixing, the mixture was incubated in a 70°C water bath for 30 min. After cooling to room temperature, 0.3 M HCl solution was added for neutralization, followed by the addition of chloroform. The mixture was extracted multiple times to remove excess PMP. Finally, the aqueous layer was filtered through a 0.22 μm microporous membrane and analyzed by HPLC.

[0086] Take 5 mg of BEP-1A sample and hydrolyze it with 3M trifluoroacetic acid (TFA) at 120℃ for 5 h. Add methanol and concentrate under reduced pressure to dryness, repeating the process to remove excess TFA. Add an appropriate amount of ultrapure water to dissolve the hydrolysis product, and derivatize the sample using the PMP monosaccharide standard derivatization method. Filter the derivatized product through a 0.22 μm microporous membrane and analyze it using high performance liquid chromatography.

[0087] The chromatograms of the monosaccharide composition of the mixed monosaccharide standard and BEP-1A are shown below. Figure 4 As shown; Figure 4 In the figure, A represents the chromatogram of the mixed monosaccharide standard; Figure 4 In the image, B represents the monosaccharide composition chromatogram of BEP-1A. (The remaining text appears to be a fragment and requires further context for accurate translation.) Figure 4It is known that BEP-1A is mainly composed of mannose, glucose and galactose, with the molar ratio of each component being 0.11:4.3:1.3.

[0088] (4) Infrared spectral detection of BEP-1A monosaccharide

[0089] In 4000-400cm -1 The BEP-1A was scanned using a Fourier transform infrared spectrometer within the wavenumber range, and its infrared spectrum was recorded. The infrared spectrum of the BEP-1A is shown below. Figure 5 As shown. Figure 5 Comparison of relevant signals with literature shows that at 3389.76 cm⁻¹ -1 The broad absorption peak at 2932.72 cm⁻¹ belongs to the stretching vibration of the hydroxyl group (OH). -1 The broad absorption peak at 1641 cm⁻¹ belongs to the CH stretching vibration. -1 The signal at this location indicates the presence of bound water in the polysaccharide; 1148.88 cm -1 1053.91cm -1 and 1040.89cm -1 The signal is attributed to the pyranose ring of BEP-1A; 918.43 cm -1 and 808.99cm -1 The absorption peaks at these locations indicate that BEP-1A contains β-configuration and α-configuration glycosidic bonds, respectively.

[0090] (5) Analysis of the linkage mode of BEP-1A sugar chains

[0091] The glycosidic bond linkage mode of BEP-1A was detected and analyzed using a methylation experiment. BEP-1A samples were treated with methylation, acid hydrolysis, and acetylation to obtain sugar alcohol acetate compounds. These compounds were analyzed by GC-MS and compared with relevant databases and literature to obtain information such as glycosidic bond type, content and ratio of various sugar residues. The results are shown in Table 1.

[0092] Table 1. Results of BEP-1A methylation analysis

[0093]

[0094] As shown in Table 1, the repeatable primary structural units of BEP-1A include: Glcp-(1→,→3-Glcp-(1→,→3)-Manp-(1→,→2)-Galp-(1→,→2)-Glcp-(1→,→4)-Galp-(1→,→4)-Glcp-(1→ and→2,6)-Galp-(1→, a total of 8 sugar residues.

[0095] The primary structure of BEP-1A is as follows:

[0096]

[0097] Its main chain consists of β-1,3-Glcp, β-1,2-Glcp, α-1,3-Manp, α-1,4-Galp, α-1,4-Glcp and α-1,6-Galp, among which the O-2 position of α-1,6-Galp contains a branch chain, which consists of α-1,2-Galp and α-1-Glcp.

[0098] (6) Nuclear magnetic resonance analysis of BEP-1A

[0099] 30 mg of BEP-1A was repeatedly dissolved in deuterated water, lyophilized three times, and finally dissolved in 500 μL of deuterated water for detection using a Bruker 600M nuclear magnetic resonance spectrometer. Record the results. 1 H NMR, 13 C NMR, 1 H- 1 H-correlation spectrum (COSY), heteronuclear single quantum correlation spectrum (HSQC), and heteronuclear multiple quantum correlation spectrum (HMBC).

[0100] BEP-1A 1 H spectrum and 13 The C-spectrums are as follows: Figure 6 and Figure 7 As shown. The HSQC spectrum of BEP-1A is as follows. Figure 8 As shown. BEP-1A 1 H- 1 H COSY spectrum as shown Figure 9 As shown. The HMBC spectrum of BEP-1A is as follows. Figure 10 As shown. Different sugar residues 1 H and 13 The chemical shifts of C are assigned as shown in Table 2.

[0101] Table 2 BEP-1A sugar residues 13 C 1 H chemical shift assignment

[0102]

[0103] Example 3: Effect of BEP-1A on RAW 264.7 cell proliferation

[0104] RAW 264.7 cells in logarithmic growth phase were divided into groups of 4 × 10⁻⁶. 4Cells were seeded per well in 96-well plates, with 100 μL of cell suspension added to each well. The cells were cultured overnight. After cell attachment, the cells were divided into 6 groups, and the old culture medium was discarded. The control group received complete culture medium, the treatment groups received different final concentrations (25, 50, 100, 200 μg / mL) of BEP-1A solution, and the positive control group received LPS solution with a final concentration of 1 μg / mL. 24 h after treatment, the cell culture medium was discarded, and 110 μL of complete culture medium (containing 10 μL CCK-8) was added. The cells were incubated in a cell culture incubator for 1 h, and the absorbance was measured at 450 nm using a full-wavelength microplate reader.

[0105] The results of the effect of BEP-1A on the proliferation of RAW 264.7 cells are as follows: Figure 11 As shown. By Figure 11 It was found that within the concentration range of 25–200 μg / mL, BEP-1A significantly promoted the proliferation of RAW 264.7 cells in a dose-dependent manner. These results indicate that BEP-1A has no cytotoxic effect on RAW 264.7 cells and can promote their growth.

[0106] Example 4: Effect of BEP-1A on nitric oxide (NO) in RAW 264.7 cells

[0107] RAW 264.7 cells in logarithmic growth phase were divided into groups of 4 × 10⁻⁶. 4 Cells were seeded per well in 96-well plates, with 100 μL of cell suspension added to each well. After overnight culture, the cells were divided into 6 groups, and the old culture medium was discarded. The control group received complete culture medium, the drug-treated groups received different final concentrations (25, 50, 100, 200 μg / mL) of BEP-1A solution, and the positive control group received LPS solution with a final concentration of 1 μg / mL. Twenty-four hours after drug administration, the culture supernatant was collected, and a NO standard curve was plotted according to the NO kit instructions. The NO content secreted by cells in each group was then measured and calculated.

[0108] The effect of BEP-1A on NO release in RAW 264.7 cells is as follows: Figure 12 As shown. By Figure 12 It was found that, compared with the blank control group, administration of BEP-1A significantly increased the NO content secreted by RAW 264.7 cells in a dose-dependent manner. The increase in NO release preliminarily indicates that the polysaccharide BEP-1A has immunomodulatory activity.

[0109] Example 5: Effect of BEP-1A on phagocytic function of RAW 264.7 cells

[0110] This invention utilizes the FITC-Dextran phagocytosis assay to detect the effect of BEP-1A on the phagocytic function of RAW 264.7 cells. RAW 264.7 cells in the logarithmic growth phase were collected and the cell density was adjusted to 5 × 10⁻⁶ cells / year. 5 Cells were seeded at a density of 1 mL / mL in confocal microscopy dishes, with each well containing 1 mL. The dishes were incubated overnight at 37°C. After overnight adhesion, the old culture medium was discarded, and blank culture medium, LPS (1 μg / mL), and BEP-1A (200 μg / mL) solutions were added. 24 h after drug administration, 1 mL of FITC-Dextran solution (1 mg / mL) prepared with serum-free medium was added to each dish, and the dishes were incubated at 37°C for 1 h. After incubation, the cells were gently washed three times with PBS, and 200 μL / dish of anti-fluorescence quencher containing Hoechst 33342 was added. The cells were then observed and photographed using a confocal microscope.

[0111] The effect of BEP-1A on the phagocytic function of RAW 264.7 cells, as detected by the FITC-Dextran phagocytosis assay, is as follows: Figure 13 As shown. By Figure 13 It is known that BEP-1A can enhance the phagocytosis of FITC-Dextran by RAW264.7 cells. Phagocytosis is the most critical step for macrophages to defend against and clear pathogens, indicating that BEP-1A has an immunostimulatory effect on RAW264.7 cells.

[0112] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.

Claims

1. A method for extracting extracellular polysaccharides from Bifidobacterium adolescentis, characterized in that, Includes the following steps: S1. Fermentation culture of Bifidobacterium adolescentis and collection of fermentation broth; the culture medium used for fermentation culture is MRS broth medium containing 0.5 g / L L-cysteine ​​hydrochloride; the Bifidobacterium adolescentis is Bifidobacterium adolescentis strain ATCC15703; S2. Remove the bacterial cells from the fermentation broth and inactivate the enzymes contained therein, precipitate with 95% ethanol, and collect the precipitate; S3. Dissolve the precipitate obtained from S2, add papain for enzymatic hydrolysis, remove protein with Sevag reagent, evaporate the supernatant to dryness to remove organic solvent after protein removal, then dissolve in water, place in a dialysis bag with a molecular weight cutoff of 3500 Da for dialyzing, freeze-dry the dialyzed solution to obtain crude extracellular polysaccharide of Bifidobacterium adolescentis, and then remove pigments from the obtained crude extracellular polysaccharide using AB-8 macroporous adsorption resin to obtain decolorized crude polysaccharide; S4. The decolorized crude polysaccharide was separated and purified by anion exchange column chromatography, eluted with ultrapure water, and the fraction obtained after elution with ultrapure water was collected; the anion exchange column chromatography used was DEAE cellulose DE-52 anion exchange column chromatography; S5. The fraction obtained in S4 was separated and purified by gel column chromatography. Ultrapure water was used for elution, and the absorbance of the eluent at 490 nm was detected by the phenol-sulfuric acid method in a separate tube to plot the elution curve. The eluent fractions from the first peak to the peak tip were collected in four tubes. The gel column chromatography used was Sephacryl S-500 HR propylene dextran gel column chromatography.

2. The extraction method according to claim 1, characterized in that, The method to inactivate the enzymes contained in S2 is to boil for 25–35 minutes.

3. The extraction method according to claim 1, characterized in that, Add 3.8 to 4.2 times the volume of 95% ethanol to S2 for alcohol precipitation.

4. The extraction method according to claim 1, characterized in that, The final concentration of papain in S3 is 1.8–2.2 mg / mL, and the enzyme is digested by reacting at 58–60℃ for 55–65 min.

5. The extraction method according to claim 1, characterized in that, The Sevag reagent described in S3 consists of chloroform and n-butanol in a volume ratio of 4:

1.

6. An extracellular polysaccharide of Bifidobacterium adolescentis, characterized in that, Obtained by the extraction method described in any one of claims 1 to 5.

7. The use of the extracellular polysaccharide of Bifidobacterium adolescentis according to claim 6 in the preparation of immunomodulatory products.

8. An immunomodulatory product, characterized in that, It contains the extracellular polysaccharide of Bifidobacterium adolescentis as described in claim 6.